In the series we cover:
The progressive nature of Spinal Muscular Atrophy (SMA) means that the sooner someone is diagnosed; the sooner intervention can be made with treatments that can change the course of the disease. The programme features a report on Biogen, innovators in treatments for neurological conditions and collaborates with different stakeholders to find solutions for the SMA community.
Also on the programme is the pharmaceutical company Novartis who uses data science and digital technology while working with medical teams, to provide continuity across healthcare, particularly cancer treatments. The company has developed digital tools to ensure that patients can be monitored remotely and ultimately, putting the patient first.
A special report on pain features Grünenthal, who sees palliative care as a moral duty and human right and believes that end of life care should be achievable and accessible worldwide. Grünenthal has developed comprehensive care systems that include psychological, spiritual and social support for the patient and their families.
Leo Pharma works in partnership with patients to gain a better understanding of diseases and chronic conditions, and the treatment plan that is needed. The company feels it is vital for patients to be involved in all the key steps as nobody is more informed than someone living with the condition.
Inflammatory Bowel Disease has a mental as well as physical impact on patients. ‘We Won’t Rest: Working Together Towards Better Patient Outcomes’ features the biopharmaceutical bompany Pfizer who has developed a Lifestyle Management care platform in partnership with SideKick Health, to help people take control of their conditions by maintaining a healthier lifestyle and overall well-being.